Neoadjuvant pembrolizumab-based therapy versus dual HER2 blockade in early breast cancer: comparable surgical complication rates in a real-world cohort
Authors:
Open Access
- 3 September 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1917346
Abstract
Background: Neoadjuvant systemic therapy (NST) has become a cornerstone in the management of aggressive early breast cancer (BC) subtypes, including triple-negative (eTNBC) and HER2-positive disease. Immune checkpoint inhibition with pembrolizumab represents an active immunotherapeutic approach, whereas dual HER2 blockade with trastuzumab and pertuzumab constitutes passive immunotherapy in early HER2-positive BC. Although both strategies demonstrate substantial antitumor efficacy, real-world data directly comparing their surgical safety profiles are limited. Materials and methods: This retrospective single-center cohort study included 99 patients with early BC treated with NST between 2014 and 2025. A total of 33 patients with TNBC received pembrolizumab-based therapy according to the KEYNOTE-522 regimen, whereas 66 patients with HER2-positive disease received chemotherapy combined with trastuzumab and pertuzumab. Surgical adverse events within 30 days postoperatively were assessed using the Clavien–Dindo classification and the Comprehensive Complication Index (CCI). Complication rates and severity were compared between groups. Results: The overall postoperative complication rate was 25.3%, with no significant difference between TNBC and HER2-positive cohorts (27.3% vs. 24.2%, p = 0.744). Most complications were minor (Clavien–Dindo ≤II), and rates of major complications (≥IIIa) did not differ between groups ( p = 0.706). Mean CCI scores were comparable (22.1 vs. 24.4; p = 0.630). Seroma formation was the most frequent adverse event in both cohorts. In an exploratory multivariable logistic regression analysis, treatment group was not independently associated with postoperative complications. Pathological complete response rates were 63.6% in TNBC and 45.5% in HER2-positive patients. No clinically relevant delays in adjuvant radiotherapy occurred. Conclusion: No statistically significant differences in postoperative morbidity were observed between treatment groups. These findings support the feasibility of integrating both neoadjuvant treatment strategies into routine surgical practice; however, confirmation in larger prospective studies is warranted.Keywords
This publication has 44 references indexed in Scilit:
- Surgical outcomes following neoadjuvant chemotherapy with and without immunotherapy in patients with triple-negative breast cancerDiscover Oncology, 2024
- Impact of neoadjuvant chemotherapy on the safety and long-term outcomes of patients undergoing immediate breast reconstruction after mastectomyBreast Cancer, 2024
- Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522Annals of Oncology, 2024
- Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2023
- Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapiesBreast Cancer Research and Treatment, 2021
- Evaluation of breast surgical oncology complications after single agent versus dual agent HER2 targeted neoadjuvant chemotherapyThe American Journal of Surgery, 2020
- HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine DevelopmentArchivum Immunologiae et Therapiae Experimentalis, 2020
- Immune‐Related Adverse Events From Immune Checkpoint InhibitorsClinical Pharmacology & Therapeutics, 2016
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast CancerJAMA, 2013
- Impact of Chemotherapy on Postoperative Complications After Mastectomy and Immediate Breast ReconstructionArchives of Surgery, 2010